Lampalizumab
Lampalizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against complement factor D.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
206 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 19 | 23 | 7 | 1 | 1 | 42 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 4 | 2 | — | 1 | — | 6 |
| Leukemia | D007938 | — | C95 | 2 | 1 | 2 | 1 | — | 5 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 3 | — | 1 | — | 4 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | 1 | — | 1 | 1 | 3 |
| Malaria | D008288 | EFO_0001068 | B54 | — | — | — | 2 | — | 2 |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 1 | — | — | 1 | — | 2 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | 1 | 1 | 2 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | 2 | — | 2 |
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | — | — | 1 | — | 1 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 8 | 15 | 14 | — | — | 35 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 4 | 1 | — | — | 7 |
| Hodgkin disease | D006689 | — | C81 | 2 | 4 | 1 | — | — | 7 |
| Geographic atrophy | D057092 | — | — | 1 | 3 | 3 | — | — | 7 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 3 | 2 | — | — | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | 1 | — | — | 4 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 1 | 1 | — | — | 4 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 2 | 1 | — | — | 4 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 1 | 2 | — | — | 3 |
| Primary myelofibrosis | D055728 | — | D47.4 | 2 | — | 1 | — | — | 3 |
Show 32 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 10 | 11 | — | — | — | 17 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 3 | — | — | — | 6 |
| Follicular lymphoma | D008224 | — | C82 | 2 | 4 | — | — | — | 5 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | 5 | — | — | — | 5 |
| Rhabdomyosarcoma | D012208 | — | — | 2 | 3 | — | — | 1 | 4 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 2 | 3 | — | — | — | 4 |
| Eyelid neoplasms | D005142 | EFO_1000934 | — | 2 | 2 | — | — | — | 4 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 3 | 3 | — | — | — | 4 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 2 | 1 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 3 |
Show 51 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
| Thrombocytosis | D013922 | HP_0001894 | D75.83 | 1 | — | — | — | — | 1 |
| Hiv | D006678 | — | O98.7 | 1 | — | — | — | — | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | — | — | — | 1 | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 1 | 1 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | — | — | 1 | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 1 | 1 |
| Germ cell and embryonal neoplasms | D009373 | — | — | — | — | — | — | 1 | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | — | — | — | — | 1 | 1 |
| Retinal neoplasms | D019572 | — | C69.2 | — | — | — | — | 1 | 1 |
| Phenylketonurias | D010661 | — | E70.0 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lampalizumab |
| INN | lampalizumab |
| Description | Lampalizumab (humanized mab) |
| Classification | Antibody |
| Drug class | ionotropic non-NMDA (N-methyl D-aspartate) glutamate receptors [AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) and/or KA (kainite antagonist) receptors]; monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109408 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | UWU93Y99R3 (ChemIDplus, GSRS) |
Target
Agency Approved
CFD
CFD
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 301 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use